[go: up one dir, main page]

MX2017003989A - Alfa-glucosidasa acida altamente potente con carbohidratos mejorados. - Google Patents

Alfa-glucosidasa acida altamente potente con carbohidratos mejorados.

Info

Publication number
MX2017003989A
MX2017003989A MX2017003989A MX2017003989A MX2017003989A MX 2017003989 A MX2017003989 A MX 2017003989A MX 2017003989 A MX2017003989 A MX 2017003989A MX 2017003989 A MX2017003989 A MX 2017003989A MX 2017003989 A MX2017003989 A MX 2017003989A
Authority
MX
Mexico
Prior art keywords
rhgaa
glucosidase
highly potent
acid alpha
carbohydrates
Prior art date
Application number
MX2017003989A
Other languages
English (en)
Other versions
MX388241B (es
Inventor
Do Hung
Gotschall Russell
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2017003989A publication Critical patent/MX2017003989A/es
Publication of MX388241B publication Critical patent/MX388241B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La composición alfa glucosidasa humana recombinante (rhGAA) derivada de las células CHO que contiene una composición glicana más optimizada que consiste de una cantidad más elevada de rhGAA que contiene N-glicanos que portan manosa-6-fosfato (M6P) o bis-M6P que las rhGAA, junto con baja cantidad de glicanos de manosa alta no fosforilada, y baja cantidad de galactosa terminal en oligosacáridos complejos. Se describen las composiciones que contienen la rhGAA, y métodos de uso.
MX2017003989A 2014-09-30 2015-09-30 Alfa-glucosidasa ácida altamente potente con carbohidratos mejorados. MX388241B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462057847P 2014-09-30 2014-09-30
US201462057842P 2014-09-30 2014-09-30
US201562112463P 2015-02-05 2015-02-05
US201562135345P 2015-03-19 2015-03-19
PCT/US2015/053252 WO2016054231A1 (en) 2014-09-30 2015-09-30 Highly potent acid alpha-glucosidase with enhanced carbohydrates

Publications (2)

Publication Number Publication Date
MX2017003989A true MX2017003989A (es) 2017-07-07
MX388241B MX388241B (es) 2025-03-19

Family

ID=55631441

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003989A MX388241B (es) 2014-09-30 2015-09-30 Alfa-glucosidasa ácida altamente potente con carbohidratos mejorados.
MX2021014565A MX2021014565A (es) 2014-09-30 2017-03-27 Alfa-glucosidasa acida altamente potente con carbohidratos mejorados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014565A MX2021014565A (es) 2014-09-30 2017-03-27 Alfa-glucosidasa acida altamente potente con carbohidratos mejorados.

Country Status (39)

Country Link
US (6) US10208299B2 (es)
EP (3) EP3201320B1 (es)
JP (3) JP6851964B2 (es)
KR (4) KR102455814B1 (es)
CN (2) CN107075468B (es)
AU (3) AU2015325028B2 (es)
BR (1) BR112017005810A2 (es)
CA (2) CA2961762C (es)
CL (1) CL2017000722A1 (es)
CO (1) CO2017002776A2 (es)
CR (1) CR20170107A (es)
CY (2) CY1126544T1 (es)
DK (2) DK3201320T5 (es)
DO (1) DOP2017000079A (es)
EA (1) EA038986B1 (es)
EC (1) ECSP17019103A (es)
ES (2) ES2967620T3 (es)
FI (4) FI3201320T3 (es)
FR (2) FR24C1012I1 (es)
HR (2) HRP20250058T1 (es)
HU (4) HUE070443T2 (es)
IL (4) IL289383B2 (es)
LT (4) LT4273241T (es)
MX (2) MX388241B (es)
MY (1) MY186336A (es)
NI (1) NI201700039A (es)
NO (1) NO2025023I1 (es)
PE (1) PE20170906A1 (es)
PH (1) PH12017500455A1 (es)
PL (2) PL4273241T3 (es)
PT (2) PT3201320T (es)
RS (2) RS65066B1 (es)
SG (2) SG10202003753PA (es)
SI (2) SI4273241T1 (es)
SM (2) SMT202400010T1 (es)
SV (1) SV2017005416A (es)
TN (1) TN2017000082A1 (es)
WO (1) WO2016054231A1 (es)
ZA (2) ZA201701945B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967620T3 (es) 2014-09-30 2024-05-03 Amicus Therapeutics Inc Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados
KR102510941B1 (ko) * 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
HRP20210894T1 (hr) * 2015-12-30 2021-07-23 Amicus Therapeutics, Inc. Poboljšana kisela alfa-glukozidaza za liječenje pompeove bolesti
CN118581067A (zh) * 2016-03-30 2024-09-03 阿米库斯治疗学公司 用于选择高m6p重组蛋白的方法
IL319770A (en) 2016-03-30 2025-05-01 Amicus Therapeutics Inc Method for selecting recombinant proteins with high mannose-6-phosphate content
KR102758570B1 (ko) 2016-03-30 2025-01-23 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
JP2020503900A (ja) * 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
EP3624831B1 (en) * 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
AU2020343680A1 (en) * 2019-09-06 2022-03-24 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
KR20230155622A (ko) * 2021-02-11 2023-11-10 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 인간 산성 알파-글루코시다제 및 이의 용도
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
JP2025515159A (ja) 2022-05-05 2025-05-13 アミカス セラピューティックス インコーポレイテッド ポンペ病の治療方法
TW202436620A (zh) 2022-12-02 2024-09-16 美商阿米庫斯醫療股份有限公司 用於在兒科患者中治療嬰兒型龐貝氏症之方法
JP2025540119A (ja) 2022-12-02 2025-12-11 アミカス セラピューティックス インコーポレイテッド 小児患者の遅発型ポンペ病の治療方法
WO2026006625A1 (en) 2024-06-26 2026-01-02 Amicus Therapeutics, Inc. Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
CA2309321A1 (en) 1997-11-10 1999-05-20 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ATE410506T1 (de) 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
CA2362914C (en) 1999-02-12 2009-04-14 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
CA2378776A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
TWI280882B (en) 2000-07-18 2007-05-11 Univ Duke Composition for the treatment of glycogen storage disease type-II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
MXPA04003640A (es) 2001-10-16 2005-04-11 Rxkinetix Inc Formulaciones de proteina de alta concentracion y metodo de fabricacion.
AU2003224880A1 (en) 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
DK1589993T3 (en) 2003-01-31 2015-03-09 Sinai School Medicine COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) * 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
CA2612538C (en) 2005-05-17 2015-06-30 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101636200A (zh) * 2006-11-13 2010-01-27 齐斯特治疗公司 用于治疗庞贝氏症的方法
JP2010509344A (ja) 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
PL3470077T3 (pl) 2008-02-12 2021-04-06 Amicus Therapeutics, Inc. Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi
WO2009114679A2 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
AU2009223125A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for Pompe disease
PT2279210T (pt) * 2008-05-07 2017-07-10 Biomarin Pharm Inc Péptidos de direcionamento lisossomal e suas utilizações
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
ES2735023T3 (es) * 2008-12-16 2019-12-13 Genzyme Corp Intermedios sintéticos para preparar conjugados de oligosacáridos-proteínas
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
NZ595629A (en) 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating lysosomal storage disorders
ES2758827T3 (es) 2009-06-17 2020-05-06 Biomarin Pharm Inc Formulaciones para enzimas lisosómicas
JP5415170B2 (ja) 2009-07-21 2014-02-12 富士フイルム株式会社 複眼撮像装置
CN102712914A (zh) * 2009-09-29 2012-10-03 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
CN103328646B (zh) * 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
SG10201605874TA (en) 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
BR112013030432A2 (pt) * 2011-05-27 2016-12-13 Callidus Biopharma Inc método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013016249A2 (en) * 2011-07-22 2013-01-31 Insight Photonic Solutions, Inc. System and method of dynamic and adaptive creation of a wavelength-continuous and prescribed wavelength versus time sweep from a laser
BR112014014808A2 (pt) 2011-12-22 2018-09-25 Centogene Ip Gmbh combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação
US9404100B2 (en) 2012-03-07 2016-08-02 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of Pompe disease
HRP20210398T1 (hr) 2012-05-03 2021-05-28 Amicus Therapeutics, Inc. Režimi doziranja za liječenje pompeove bolesti
CA2915127A1 (en) 2012-06-06 2013-12-12 Giancarlo PARENTI Allosteric chaperones and uses thereof
TWI529396B (zh) 2014-07-18 2016-04-11 Mpi Corp Probe card and its transfer circuit board and signal feed structure
ES2967620T3 (es) 2014-09-30 2024-05-03 Amicus Therapeutics Inc Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados

Also Published As

Publication number Publication date
PE20170906A1 (es) 2017-07-12
KR20220146662A (ko) 2022-11-01
EP3201320A1 (en) 2017-08-09
FI4273241T3 (fi) 2025-03-08
ECSP17019103A (es) 2017-06-30
CL2017000722A1 (es) 2017-12-15
IL277529A (en) 2020-11-30
US20260015600A1 (en) 2026-01-15
EP3201320B1 (en) 2023-10-11
IL289383A (en) 2022-02-01
IL251152A0 (en) 2017-04-30
AU2015325028B2 (en) 2022-02-24
MX2021014565A (es) 2022-01-11
HUE070443T2 (hu) 2025-06-28
IL307587A (en) 2023-12-01
US20220162578A1 (en) 2022-05-26
AU2015325028A1 (en) 2017-03-16
CA2961762A1 (en) 2016-04-07
US20190276812A1 (en) 2019-09-12
ES3017134T3 (en) 2025-05-12
AU2022203498A1 (en) 2022-06-09
PH12017500455A1 (en) 2017-07-31
KR20250004926A (ko) 2025-01-08
PT3201320T (pt) 2024-01-12
JP6851964B2 (ja) 2021-03-31
PL4273241T3 (pl) 2025-04-14
RS66510B1 (sr) 2025-03-31
EP4455283A2 (en) 2024-10-30
EP4273241A2 (en) 2023-11-08
IL289383B1 (en) 2023-11-01
CR20170107A (es) 2017-09-01
BR112017005810A2 (pt) 2018-02-27
CY2024009I2 (el) 2025-05-09
CN114540327A (zh) 2022-05-27
ZA201701945B (en) 2019-06-26
DK3201320T3 (da) 2024-01-08
ZA201901690B (en) 2022-06-29
RS65066B1 (sr) 2024-02-29
PL3201320T3 (pl) 2024-03-18
KR102455814B1 (ko) 2022-10-18
DK3201320T5 (da) 2024-10-14
US11591583B2 (en) 2023-02-28
EP4455283A3 (en) 2025-01-22
LTPA2025521I1 (es) 2025-06-25
JP2017537604A (ja) 2017-12-21
HUE064629T2 (hu) 2024-04-28
EP4273241A3 (en) 2024-01-24
IL289383B2 (en) 2024-03-01
FR25C1019I1 (fr) 2025-08-01
FR24C1012I1 (fr) 2024-05-24
CY2024009I1 (el) 2025-05-09
SG10202003753PA (en) 2020-05-28
US20210261935A1 (en) 2021-08-26
MY186336A (en) 2021-07-13
EP4273241B1 (en) 2024-12-04
FIC20250020I1 (fi) 2025-05-21
EA201790724A1 (ru) 2017-08-31
JP2021011489A (ja) 2021-02-04
CN107075468B (zh) 2021-12-24
JP7225176B2 (ja) 2023-02-20
LT4273241T (lt) 2025-02-10
SMT202500074T1 (it) 2025-03-12
IL251152B (en) 2021-06-30
EA038986B1 (ru) 2021-11-18
NI201700039A (es) 2018-01-05
FI3201320T3 (fi) 2024-01-08
HUS2500025I1 (hu) 2025-06-28
US20230203465A1 (en) 2023-06-29
US11753632B2 (en) 2023-09-12
CA3228032A1 (en) 2016-04-07
PT4273241T (pt) 2025-02-24
MX388241B (es) 2025-03-19
CO2017002776A2 (es) 2017-08-10
AU2025201108A1 (en) 2025-03-06
IL277529B (en) 2022-02-01
SV2017005416A (es) 2017-08-08
SI4273241T1 (sl) 2025-03-31
JP2023078118A (ja) 2023-06-06
TN2017000082A1 (en) 2018-07-04
US20170298335A1 (en) 2017-10-19
CN107075468A (zh) 2017-08-18
CY1126544T1 (el) 2025-05-09
HUS2400007I1 (hu) 2024-04-28
FIC20240010I1 (fi) 2024-04-03
DOP2017000079A (es) 2017-05-31
ES2967620T3 (es) 2024-05-03
NO2025023I1 (no) 2025-05-23
WO2016054231A1 (en) 2016-04-07
LT3201320T (lt) 2024-01-25
NZ768484A (en) 2024-05-31
DK4273241T3 (da) 2025-02-24
SMT202400010T1 (it) 2024-03-13
EP3201320A4 (en) 2018-03-14
KR102741048B1 (ko) 2024-12-11
KR102306577B1 (ko) 2021-10-01
KR20210118977A (ko) 2021-10-01
NZ729507A (en) 2021-10-29
LTPA2024509I1 (es) 2024-04-25
SG11201702114TA (en) 2017-04-27
US10961522B2 (en) 2021-03-30
HRP20250058T1 (hr) 2025-03-28
HRP20240041T1 (hr) 2024-03-29
US10208299B2 (en) 2019-02-19
CA2961762C (en) 2024-03-05
SI3201320T1 (sl) 2024-02-29
AU2022203498B2 (en) 2025-03-13
KR20170063837A (ko) 2017-06-08

Similar Documents

Publication Publication Date Title
MX2017003989A (es) Alfa-glucosidasa acida altamente potente con carbohidratos mejorados.
BR112016015105A2 (pt) Conjugados var2csa-droga
EP4368992A3 (en) Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
BR112017018919A8 (pt) Proteínas de fusão imunomoduladoras e seus usos
BR112018067696A2 (pt) membros de ligação à pd-l1
MX2021000229A (es) Composiciones oligosacaridicas y metodos para la produccion de estas.
MX2020000969A (es) Sialil-transferasas y su uso en la produccion de oligosacaridos sialilados.
BR112014026755B8 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
PH12017501341A1 (en) Oligosaccharide compositions for use as food ingredients and methods of producing thereof
BR112017005997A2 (pt) método
MX2018015517A (es) Glicosilacion enzimatica de glucosidos de esteviol y otros compuestos con glucosa-1-fosfato.
BR112014007146A8 (pt) Vedação com fator reduzido de formato para terminação/fibra óptica para cabo blindado
BR112019008048A2 (pt) método para preparar rebaudiosídeo n com o uso de método enzimático
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
MX2016013473A (es) Pared celular de levadura enriquecida en proteina de manano-oligosacarido.
WO2015100160A3 (en) Transgenic production of heparin
PH12018502656A1 (en) Engineered beta-glucosidases and glycosylation methods
CR20160225A (es) Glicoproteínas recombinantes y sus usos
PE20151999A1 (es) Composiciones nutricionales que contienen un componente peptidico y usos del mismo
BR112022011595A2 (pt) Composições de higiene bucal e métodos de uso
WO2014155395A3 (en) Glucan branching enzymes and their methods of use
BR112012033245B8 (pt) Composições límpidas para limpeza da pele, de baixa irritação e com ph relativamente baixo
MX2022001680A (es) Proteinas de fusion contra glucoesfingolipidos sialosilados y glucoproteinas sialiladas, y usos de los mismos.
BR112018070189A2 (pt) método para seleção de proteínas recombinantes ricas em m6p